Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for MDXG.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
June 30, 2026 17.21M
March 31, 2026 17.59M
December 31, 2025 21.21M
September 30, 2025 18.21M
June 30, 2025 18.46M
March 31, 2025 18.66M
December 31, 2024 23.54M
September 30, 2024 19.02M
June 30, 2024 19.25M
March 31, 2024 19.45M
December 31, 2023 49.05M
September 30, 2023 48.97M
June 30, 2023 48.84M
March 31, 2023 48.71M
December 31, 2022 51.08M
September 30, 2022 48.48M
June 30, 2022 48.36M
March 31, 2022 48.24M
December 31, 2021 52.09M
September 30, 2021 48.02M
June 30, 2021 47.90M
March 31, 2021 50.44M
December 31, 2020 50.66M
September 30, 2020 48.03M
June 30, 2020 67.52M
Date Value
March 31, 2020 68.00M
December 31, 2019 68.58M
September 30, 2019 69.14M
June 30, 2019 66.82M
March 31, 2019 0.00
December 31, 2018 0.229M
September 30, 2018 0.00
June 30, 2018 0.00
March 31, 2018 0.00
December 31, 2017 0.286M
September 30, 2017 0.0086M
June 30, 2017 0.015M
March 31, 2017 0.021M
December 31, 2016 0.031M
September 30, 2016 0.041M
June 30, 2016 0.072M
March 31, 2016 0.103M
December 31, 2015 0.133M
September 30, 2015 0.163M
June 30, 2015 0.192M
March 31, 2015 0.221M
December 31, 2014 0.00
September 30, 2014 0.2777M
June 30, 2014 0.3055M
March 31, 2014 0.00

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Anika Therapeutics, Inc. 23.32M
Perspective Therapeutics, Inc. 2.866M
ABVC BioPharma, Inc. 1.406M
Enovis Corp. 1.344B
Edwards Lifesciences Corp. 680.30M